Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the United States Medicare Fee-for-Service Population
Patients who were persistent on relugolix demonstrated high adherence throughout the study, regardless of metastatic status. These results suggest that relugolix has practical utility in real-world clinical practice.
Authors
- М. В. Шаповал
- Juan Razo
- Christine Ferro
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- Scott C. Flanders
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Benjamin Li (ORCID: https://orcid.org/0000-0001-6244-7818)
- Agnes Hong
Institutions
- Cedars-Sinai Medical Center (US)
- Pfizer (United States) (US)
- University of California San Diego (US)
- Durham VA Medical Center (US)
- Sumitomo Dainippon Pharma (United States) (US)
- Milliman (United States) (US)
Publication Details
- Journal
- Urology Practice
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1097/upj.0000000000000886
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca